SeaStar Medical Holding Corp (ICU) · Nov 3, 2026 · Other events

SeaStar Medical FDA clears QUELIMMUNE access hurdle

SAVE requirements fulfilled — FDA determined the SAVE Registry fulfilled HDE post-approval requirements

SeaStar Medical’s FDA decision completes QUELIMMUNE’s post-approval registry requirements, potentially widening hospital access while adult trial risk remains.

SeaStar Medical is a commercial-stage device company trying to turn its pediatric QUELIMMUNE approval into hospital adoption while advancing a much larger adult AKI program. QUELIMMUNE has been commercially available since 2024, and the company is simultaneously running the 339-patient NEUTRALIZE-AKI pivotal trial in adults; recent company updates described growing pediatric hospital adoption and progress toward completing that adult trial.

The FDA decision removes a real adoption bottleneck. The SAVE Registry was a post-approval requirement tied to QUELIMMUNE’s Humanitarian Device Exemption, and hospitals can now use the therapy without the research infrastructure the registry required. That expands the number of centers able to treat eligible children, rather than merely adding another positive data point. 〔0〕

The supporting evidence is encouraging, but not definitive. The registry analysis showed 90-day survival of 65.1% in 43 QUELIMMUNE-treated patients versus 47.5% in 196 clinically aligned external-control patients, with a reported P value of 0.043. Those results strengthen the commercial and clinical story, but the comparison is observational and the filing still states that QUELIMMUNE’s effectiveness has not been demonstrated under the HDE.

This is meaningful for the pediatric business, not a reset of the whole company. The decision improves the path from regulatory approval to routine hospital use and makes the recent survival data more commercially actionable. But it does not approve the adult indication, prove effectiveness in a randomized trial, or remove the central NEUTRALIZE-AKI execution risk.

The formal clearance was new, while the setup was partly known. SeaStar had already completed the required registry enrollment and publicly disclosed the favorable survival analysis, so the direction was no longer a surprise; the FDA’s determination that the post-approval obligations were satisfied is the incremental development.

Bottom line: This materially strengthens SeaStar Medical’s pediatric commercialization story by removing a regulatory-use barrier, but it remains an access and evidence milestone—not full clinical validation or adult-market approval.

What to watch next

NEUTRALIZE-AKI enrollment completion, year-end 2026 or Q1 2027

Original filing on SEC EDGAR